OakChart

Sionna Therapeutics Inc

SIONHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

3.700.00 (0.00%)
2026-11-12 12:13 CET
Market cap
167.29 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-109.52 USD m
Free cash flow, TTM
-79.61 USD m
EPS diluted, TTM
-2.43
P/E
-
Compare

Price

SION against its 20, 50 and 200-day averages
2050200beatmiss
Patternshover a marker to name it
Sales mean, own scale0–100
RS 1Sales 0.00Price0.0020.0040.0019.3M38.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SIONclose 3.7020-day 3.7850-day 5.06200-day 28.603.7052w high

93.3% under the 52-week high of 54.97 on 7 Aug 2026. 52-week low 3.19 on 6 Nov 2026. Last 15 sessions, 30.4% high to low

Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average

Profile

SION
52-week range, 1% of the way up
3.1954.97

Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in researching, developing and commercializing novel medicines for cystic fibrosis. It is focused on advancing a pipeline of small molecules and complementary CFTR modulators designed to deliver transformative clinical outcomes and improve the quality of life for individuals living with cystic fibrosis. The company was founded by Greg Hurlbut and Mark Munson in August 2019 and is headquartered in Waltham, MA.

IndexRUT
Employees59
IPOFeb 07, 2025
Beta1.23
ATR, 14d0.38
Rel volume0.00
Short float17.88%
Insider own47.89%
Inst own73.53%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap167.37M
Enterprise Value-49.47M
Income-109.52M
Sales0.00M
Book/sh5.32
Cash/sh4.96
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees59
IPOFeb 07, 2025

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.70
P/C0.75
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio13.92
Current Ratio13.92
Debt/Eq0.03
LT Debt/Eq0.03
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.43
EPS next Y-2.22
EPS next Q-0.58
EPS this Y-35.54%
EPS next Y12.70%
EPS next 5Y-8.21%
EPS past 3/5Y-22.66% -
Sales past 3/5Y- -
EPS Y/Y TTM-52.03%
Sales Y/Y TTM-
EPS Q/Q-57.22%
Sales Q/Q-
EarningsNov 10 BMO
EPS/Sales Surpr.-12.98% -

Ownership

Insider Own47.89%
Insider Trans-15.14%
Inst Own73.53%
Inst Trans12.39%
ROA-36.35%
ROE-38.96%
ROIC-44.37%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-2.00%
SMA50-26.94%
SMA200-87.06%
Trades-

Technical

Shs Outstand45.21M
Shs Float23.56M
Short Float17.88%
Short Ratio2.83
Short Interest4.21M
52W High54.97 -93.27%
52W Low3.19 15.99%
Volatility9.73% 8.46%
ATR (14)0.38
RSI (14)36.66
Beta1.23
Rel Volume0.00
Avg Volume1.49M
Volume0

Performance

Perf Week-0.80%
Perf Month-15.53%
Perf Quarter-43.43%
Perf Half Y-91.42%
Perf YTD-91.01%
Perf Year-89.85%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom2.82
Target Price15.33
Prev Close3.70
Price3.70
Change %0.00%

Analyst ratings

latest 10 of 16
DateActionAnalystRating changeTargetImplied
Aug 10, 2026UpgradeRRBC Capital MktsUnderperform → Sector Perform$5+35.1%
Aug 10, 2026DowngradeWWedbushOutperform → Neutral$5+35.1%
Aug 10, 2026DowngradeSStifelBuy → Hold$7+89.2%
Aug 10, 2026DowngradeRRaymond JamesStrong Buy → Mkt Perform
Aug 10, 2026DowngradeGGuggenheimBuy → Neutral
Aug 10, 2026DowngradeCCitizensMkt Outperform → Mkt Perform
Aug 10, 2026DowngradeBBTIG ResearchBuy → Neutral
May 05, 2026InitiatedWWedbushOutperform$53+1,332.4%
Feb 24, 2026InitiatedCCitizensMkt Outperform$63+1,602.7%
Dec 01, 2025DowngradeRRBC Capital MktsSector Perform → Underperform$24+548.6%

Peers

Mkt cap
TickerCompanyMkt cap
VRTXVertex Pharmaceuticals Inc138.74B
INSMInsmed Inc26.49B
SVRASavara Inc1.10B
AVLNAvalyn Pharma Inc1.40B
ARMPArmata Pharmaceuticals Inc144.64M
ELOXEloxx Pharmaceuticals Inc52.51M
PLRXPliant Therapeutics Inc48.15M
RAREUltragenyx Pharmaceutical Inc1.68B
MISTMilestone Pharmaceuticals Inc82.44M
ZVRAZevra Therapeutics Inc720.01M

Insider trading

latest 14 of 81
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
RA CAPITAL MANAGEMENT, L.P.DirectorSep 17 '26Sale6.333,448,81121,835,0183,448,812Sep 21 06:56 PM
RA Capital Healthcare Fund, L.DirectorSep 17 '26Proposed Sale6.333,448,81121,834,318Sep 17 05:10 PM
Thompson Peter A.DirectorJul 07 '26Sale44.8685,9183,854,2812,469,959Jul 09 04:47 PM
ORBIMED ADVISORS LLCDirectorJul 07 '26Sale44.8685,9183,854,2812,469,959Jul 09 04:44 PM
Fitzpatrick JenniferChief Legal OfficerJul 06 '26Option Exercise6.1110,25062,62810,250Jul 07 04:38 PM
Fitzpatrick JenniferChief Legal OfficerJul 06 '26Sale43.6010,250446,8620Jul 07 04:38 PM
JENNIFER FITZPATRICKOfficerJul 06 '26Proposed Sale43.9910,250450,898Jul 06 04:39 PM
Thompson Peter A.DirectorJun 30 '26Sale45.50115,8445,270,9022,555,877Jul 02 04:45 PM
ORBIMED ADVISORS LLCDirectorJun 30 '26Sale45.50115,8445,270,9022,555,877Jul 02 04:42 PM
Thompson Peter A.DirectorMay 27 '26Sale44.491014,4932,671,721May 29 09:02 PM
ORBIMED ADVISORS LLCDirectorMay 27 '26Sale44.491014,4932,671,721May 29 08:57 PM
OrbiMed Private Investments VIShareholderMay 29 '26Proposed Sale42.801,082,48046,330,144May 29 06:44 PM
Thompson Peter A.DirectorMay 11 '26Sale46.22184,6398,534,0152,671,822May 11 07:14 PM
Thompson Peter A.DirectorMay 08 '26Sale44.5859,7672,664,4132,856,461May 11 07:14 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IBBiShares Biotechnology ETFAUM: 11.36B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VHTVanguard Health Care ETFAUM: 21.51B
SBIOALPS Medical Breakthroughs ETFAUM: 192.65M
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B

News

latest 14 of 120

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.720-0.637-0.7200.000.0011
2026Q22026-08-06-0.660-0.650-0.6620.000.0011
2026Q12026-05-12-0.600-0.514-0.5940.000.0010
2025Q42026-03-02-0.460-0.539-0.4570.000.0010
2025Q32025-11-05-0.460-0.484-0.4560.000.007
2025Q22025-08-11-0.410-0.555-0.4090.000.004
2025Q12025-05-12-0.620-0.448-0.3740.000.004
2024Q42025-03-20-3.380-1.277-0.3590.000.003
2026Q4---0.582--0.0011
2027Q1---0.514--0.007
2027Q2---0.501--0.007
2027Q3---0.504--0.007
2027Q4---0.490--0.005

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-15.990-5.263-1.3980.000.00
2025FY-1.880-1.996-1.8800.000.00
2026FY--2.548--0.00
2027FY--2.225--0.00
2028FY--2.382--1.67
2029FY--2.450--27.60
2030FY--2.264--58.26

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-108000.000.000.00
2026Q4S2026-08-068000.000.000.00
2026Q4S2026-07-238000.000.000.00
2026Q4S2026-06-107000.000.000.00
2026Q4S2026-05-128000.000.000.00
2026Q4S2026-05-018000.000.000.00
2026Q4S2026-03-057000.000.000.00
2026Q4S2026-03-046000.000.000.00
2026Q4S2026-03-025000.000.000.00
2026Q4S2026-02-233000.000.000.00
2026Q4S2025-11-122000.000.000.00
2026Q4S2025-11-112000.000.000.00
2026Q4S2025-11-102000.000.000.00
2026Q4R2026-11-10614-0.58-0.73-0.43

Estimate history

EPS, annual-0.912-1.071-1.398-1.683-2.4301
Period2022202320242025TTM
EPS, quarterly-0.577-0.359-0.374-0.409-0.456-0.457-0.594-0.662-0.717
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00000
Period2022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual44.12444.12444.12444.72445.214
Period2022202320242025MRQ
Shares, quarterly44.12444.12444.09244.13244.46444.72445.07645.16445.214
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue0.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.610.650.670.580.12
Gross Profit-0.61-0.65-0.67-0.58-0.12
Selling, General and Administrative Excl. Other113.6988.3369.8949.7541.25
Research and Development74.3260.2657.2940.6334.60
Other Operating Expense0.000.000.000.000.00
Operating Income-114.30-88.98-70.56-50.33-41.37
Interest Expense0.000.000.000.000.00
Unusual Expense6.200.000.000.000.00
Net Income Before Taxes-109.52-75.27-61.69-47.26-40.24
Income Taxes0.000.000.000.000.00
Consolidated Net Income-109.52-75.27-61.69-47.26-40.24
Net Income From Continuing Operations-109.52-75.27-61.69-47.26-40.24
Net Income-109.52-75.27-61.69-47.26-40.24
EPS (Recurring)-2.33-1.68-1.40-1.07-0.91
EPS (Basic, Before Extraordinaries)-2.43-1.68-1.40-1.07-0.91
EPS (Diluted)-2.43-1.68-1.40-1.07-0.91
EBITDA-113.69-88.33-69.89-49.75-41.25
Non-Operating Income (Expense)10.9813.718.873.071.13
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense24.3012.073.712.261.69
Shares Outstanding45.2144.7244.1244.1244.12
Market Capitalization167.29167.291,847.19--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.150.150.150.150.100.150.160.17
Gross Profit-0.15-0.15-0.15-0.15-0.10-0.15-0.16-0.17
Selling, General and Administrative Excl. Other28.4632.3129.4523.4623.7021.7619.5017.97
Research and Development18.3221.8618.9615.1716.0415.3813.6714.25
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-28.62-32.47-29.60-23.61-23.80-21.91-19.66-18.13
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense6.200.000.000.000.000.000.000.00
Net Income Before Taxes-32.42-29.89-26.78-20.44-20.28-18.07-16.48-15.85
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-32.42-29.89-26.78-20.44-20.28-18.07-16.48-15.85
Net Income From Continuing Operations-32.42-29.89-26.78-20.44-20.28-18.07-16.48-15.85
Net Income-32.42-29.89-26.78-20.44-20.28-18.07-16.48-15.85
EPS (Recurring)-0.62-0.66-0.59-0.46-0.46-0.41-0.37-0.36
EPS (Basic, Before Extraordinaries)-0.72-0.66-0.59-0.46-0.46-0.41-0.37-0.36
EPS (Diluted)-0.72-0.66-0.59-0.46-0.46-0.41-0.37-0.36
EBITDA-28.46-32.31-29.45-23.46-23.70-21.76-19.50-17.97
Non-Operating Income (Expense)2.402.582.823.173.533.843.182.29
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.086.846.553.833.312.842.091.06
Shares Outstanding45.2145.1645.0844.7244.4644.1344.0944.12
Market Capitalization167.291,986.161,803.971,836.031,298.15765.56461.54510.08

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments235.88147.5438.5282.61
Short Term Receivables0.000.000.000.00
Inventories0.000.000.000.00
Other Current Assets5.543.460.691.22
Total Current Assets241.42150.9939.2183.83
Net Property, Plant & Equipment9.1510.3011.732.57
Total Investments and Advances75.3821.470.960.96
Intangible Assets0.00--0.00
Deferred Tax Assets1.98---
Other Assets0.002.990.040.00
Total Assets327.93185.7551.9587.37
Short Term Debt Incl. Current Port. of LT Debt1.271.070.730.00
Accounts Payable0.771.190.720.56
Other Current Liabilities9.678.166.597.70
Total Current Liabilities11.7110.428.048.25
Long Term Debt7.418.689.750.00
Provision for Risks Charges0.000.000.000.00
Deferred Tax Liabilities1.98---
Other Liabilities0.000.000.000.00
Total Liabilities21.1019.1017.798.25
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.00330.37149.04149.04
Common Equity306.83-163.71-114.88-69.92
Total Shareholders Equity306.83166.6634.1679.12
Accumulated Minority Interest0.000.000.000.00
Total Equity306.83166.6634.1679.12
Total Liabilities & Stockholders Equity327.93185.7551.9587.37
Book Value Per Share6.86-3.71-2.60-1.58
Tangible Book Value Per Share6.86-3.71-2.60-1.58
Full-Time Employees594128-
Price to Book Ratio0.705.72--
Return on Assets-29.31-51.90-67.85-
Return on Equity-31.79-61.44-83.45-
Return on Invested Capital-23.95-35.18-107.64-50.86
Quick Ratio20.6114.494.8810.16
Current Ratio20.6114.494.8810.16

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-109.52-75.27-61.69-47.26-40.24
Depreciation0.610.650.670.580.12
Other Funds (Non Cash)25.3510.9811.313.761.29
Funds from Operations-83.56-63.65-49.71-42.92-38.83
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital4.15-2.65-3.08-0.782.76
Cash from Operating Activities-79.41-66.30-52.79-43.70-36.07
Capital Expenditures-0.20-0.38-0.03-1.12-1.87
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00
Purchase or Sale of Investments108.03-118.37-126.8928.47-27.39
Purchase of Investments-112.59-325.02-182.84-23.53-40.39
Sale Or Maturity of Investments220.62206.6555.9552.0013.00
Other Uses0.000.000.000.000.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities107.82-118.75-126.9127.35-29.26
Cash Dividends Paid0.000.000.000.000.00
Change in Capital Stock4.63205.71178.970.03110.86
Repurchase of Common Pref Stock0.000.000.000.000.00
Sale of Common Pref Stock4.63205.71178.970.03110.86
Proceedsfrom Stock Options-0.58202.07178.830.00110.79
Issuance or Reduction of Debt, Net0.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.00
Cash from Financing Activities4.63205.71178.970.03110.86
Net Change in Cash33.0520.66-0.73-16.3245.52
Free Cash Flow-79.61-66.67-52.81-44.81-37.94
Preferred Dividends (Cash Flow)-0.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments224.59211.03216.15235.88248.33262.57
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets3.945.104.815.544.004.17
Total Current Assets228.53216.13220.96241.42252.33266.75
Net Property, Plant & Equipment7.928.348.759.159.319.64
Total Investments and Advances26.1758.1974.7475.3877.6375.66
Intangible Assets---0.000.000.00
Deferred Tax Assets---1.98--
Other Assets0.640.590.580.000.000.00
Total Assets263.26283.25305.04327.93339.27352.05
Short Term Debt Incl. Current Port. of LT Debt1.431.381.321.271.221.17
Accounts Payable1.050.522.110.771.480.91
Other Current Liabilities13.948.886.349.677.155.47
Total Current Liabilities16.4210.789.7811.719.857.55
Long Term Debt6.326.697.057.417.758.07
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---1.98--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities22.7417.4716.8321.1017.6015.62
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity240.52265.77288.21306.83321.67336.43
Total Shareholders Equity240.52265.77288.21306.83321.67336.43
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity240.52265.77288.21306.83321.67336.43
Total Liabilities & Stockholders Equity263.26283.25305.04327.93339.27352.05
Book Value Per Share5.325.886.396.867.237.62
Tangible Book Value Per Share5.325.886.396.867.237.62
Full-Time Employees---59--
Price to Book Ratio0.706.885.845.693.862.17
Return on Assets-36.35-30.66-25.36-29.31-26.35-
Return on Equity-38.96-32.34-26.74-31.79-28.07-
Return on Invested Capital-13.13-10.97-9.07-6.50-6.16-5.24
Quick Ratio13.9220.0522.6020.6125.6135.33
Current Ratio13.9220.0522.6020.6125.6135.33

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-32.42-29.89-26.78-20.44-20.28-18.07
Depreciation0.150.150.150.150.190.15
Other Funds (Non Cash)7.367.186.843.962.962.16
Funds from Operations-24.90-22.55-19.78-16.32-17.13-15.76
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital6.180.33-2.06-0.301.90-2.40
Cash from Operating Activities-18.72-22.22-21.84-16.63-15.23-18.15
Capital Expenditures0.000.000.00-0.20-0.090.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments38.9521.4724.8222.7923.19-23.25
Purchase of Investments-11.35-33.03-25.33-42.88-54.14-56.42
Sale Or Maturity of Investments50.3054.5050.1565.6777.3333.17
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities38.9521.4724.8222.5923.10-23.25
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.330.751.891.661.97-0.31
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.330.751.891.661.97-0.31
Proceedsfrom Stock Options-0.03-0.23-0.320.000.00-0.32
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.330.751.891.661.97-0.31
Net Change in Cash20.56-0.004.877.629.85-41.71
Free Cash Flow-18.72-22.22-21.84-16.83-15.32-18.15

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3017.88%4.2M23.6M2.27M
2026-10-1515.60%3.7M23.6M2.20M
2026-09-3014.58%3.8M26.0M2.14M
2026-09-1515.23%4.0M26.0M1.97M
2026-08-3116.22%4.3M26.5M1.80M
2026-08-1416.04%4.2M26.5M1.59M
2026-07-3115.75%4.2M26.7M464.51K
2026-07-1519.76%5.3M26.6M432.35K
2026-06-3020.82%5.5M26.5M433.09K
2026-06-1518.92%5.0M26.4M394.28K
2026-05-2917.61%4.6M26.3M383.07K
2026-05-1518.00%4.7M26.3M360.15K
2026-04-3016.42%4.2M25.8M356.34K
2026-04-1514.77%3.8M25.7M317.83K
2026-03-3115.00%3.8M25.0M295.68K
2026-03-1314.15%3.5M25.0M304.96K
2026-02-2713.38%3.4M25.0M303.39K
2026-02-1312.34%3.1M24.8M317.34K
2026-01-3012.57%3.1M25.0M283.05K
2026-01-1512.35%3.1M24.7M309.37K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.801.500.004.0170.000.000.918-0.0100.001
call5.000.000.500.053.86361.000.000.421-0.0490.002
call7.500.000.100.053.11446.000.000.130-0.0200.001
call10.000.000.750.304.1371.000.000.111-0.0260.001
call12.500.000.750.004.7550.000.000.101-0.0270.001
call15.000.003.800.005.2370.000.000.095-0.0290.001
put2.500.000.050.057.00560.000.00-0.176-0.0600.002
put5.000.951.702.393.4377.000.00-0.579-0.0490.002
put7.503.204.400.006.0371.000.00-0.870-0.0220.001
put10.004.008.500.0014.5170.000.00-0.889-0.0240.001
put12.506.5011.000.0015.2290.000.00-0.899-0.0260.001
put15.009.0013.500.0015.7860.000.00-0.905-0.0270.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-11-09SCHEDULE 13GSEC
2026-09-21SCHEDULE 13D/ASEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-17144Filing for proposed sale of securities under Rule 144.SEC
2026-09-148-KCurrent report2026-09-09SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-07-06144Filing for proposed sale of securities under Rule 144.SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-188-KCurrent report2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090021.84M1
2026-080000
2026-07008.16M3
2026-060010.54M2
2026-050026.74M8
2026-040050.83M10
2026-0300347.02K1
2026-02002.76M4
2026-010010.00M1
2025-12003.55M9
2025-110016.33M11

Institutional holders

Manager% owned
RA CAPITAL MANAGEMENT, L.P.21.94%
TPG GP A, LLC14.39%
VIKING GLOBAL INVESTORS LP7.08%
Atlas Venture Life Science Advisors, LLC6.63%
ORBIMED ADVISORS LLC5.66%
Enavate Sciences GP, LLC5.49%
ADAGE CAPITAL PARTNERS GP, L.L.C.3.54%
JPMORGAN CHASE & CO3.30%
BlackRock, Inc.3.27%
Aberdeen Group plc2.97%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.07%
PGIM Jennison Health Sciences Fund2.06%
State Street(R) SPDR(R) S&P(R) Biotech ETF1.43%
JPMorgan Small Cap Growth Fund1.16%
iShares Russell 2000 ETF1.07%
Eventide Healthcare & Life Sciences Fund1.05%
T. Rowe Price Health Sciences Fund, Inc.0.64%
Fidelity Small Cap Index Fund0.45%
abrdn Healthcare Investors0.45%
iShares Biotechnology ETF0.41%

OakChart. SION. Cached 15 minutes.